Open AccessClinical changes induced by allergen immunotherapy with dermatophagoides pteronyssinus in local allergic rhinitis
Author(s) -
Rondon Carmen,
Campo Paloma,
Torres Maria Jose,
Galindo Luisa,
BlancaLopez Natalia,
Canto Gabriela,
Mayorga Cristobalina,
Blanca Miguel
Publication year - 2015
Publication title -
clinical and translational allergy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.979
H-Index - 37
ISSN - 2045-7022
DOI - 10.1186/2045-7022-5-s4-o4
Subject(s) - medicine , placebo , allergen , allergy , adverse effect , clinical endpoint , allergen immunotherapy , provocation test , randomized controlled trial , nasal provocation test , gastroenterology , immunology , anesthesia , pathology , alternative medicine
Methods Thirty-six subjects with LAR to DP were selected to participate in a double-blind, placebo-controlled, parallelgroup, phase II clinical trial of subcutaneous AIT in LAR. The patients were randomized to receive AIT-DP with Pangramin PLUS, ALK, DP, or placebo for a period of 24 months. The primary endpoint was total symptoms (TSS) and total medication scores (TMS). Secondary endpoints were: total combined symptom+medication scores (TCS), daily symptoms score (DSS), daily medication score (DMS), medication free days (MFD), skin testing, nasal allergen provocation test (NAPT-DP), and adverse events. Serum and nasal lavage samples were obtained for immunological studies.